CLINUVEL PHARMACEUTICALS LIMITED (CUV)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CUV - CLINUVEL PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 0.02
Index: ASX300 | ALL-ORDS

Clinuvel is a biopharmaceutical company that develops and commercialises treatments for patients with genetic, metabolic and life threatening disorders. The company was founded and listed in 2001.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$15.26

02 Jul
2024

-0.010

OPEN

$15.26

-0.07%

HIGH

$15.45

15,721

LOW

$15.26

TARGET
$18.75 22.9% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
CUV: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx 61.9 70.2 xxx
DPS (cps) xxx 5.0 6.3 xxx
EPS Growth xxx 46.6% 13.3% xxx
DPS Growth xxx 25.0% 26.7% xxx
PE Ratio xxx N/A 21.7 xxx
Dividend Yield xxx N/A 0.4% xxx
Div Pay Ratio(%) xxx 8.1% 9.0% xxx

Dividend yield today if purchased 3 years ago: 0.17%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.33

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 06/09 - ex-div 4c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx61.9
DPS All xxxxxxxxxxxxxxx5.0
Sales/Revenue xxxxxxxxxxxxxxx78.3 M
Book Value Per Share xxxxxxxxxxxxxxx333.2
Net Operating Cash Flow xxxxxxxxxxxxxxx36.9 M
Net Profit Margin xxxxxxxxxxxxxxx39.08 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx21.09 %
Return on Invested Capital xxxxxxxxxxxxxxx20.97 %
Return on Assets xxxxxxxxxxxxxxx18.04 %
Return on Equity xxxxxxxxxxxxxxx21.09 %
Return on Total Capital xxxxxxxxxxxxxxx27.98 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx33.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx0 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx157 M
Price To Book Value xxxxxxxxxxxxxxx5.37

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx1.0 M
Capex % of Sales xxxxxxxxxxxxxxx1.31 %
Cost of Goods Sold xxxxxxxxxxxxxxx28 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx10 M
Research & Development xxxxxxxxxxxxxxx1 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.8

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

18/06/2024

1

Buy

$22.25

45.81%

Bell Potter notes ongoing Phase 3 trials for Clinuvel Pharmaceuticals' Scenesse's label expansion, including patients with vitiligo.

The analyst estimates the directly addressable US vitiligo market at around 65,000-70,000 patients, translating into potential sales growth if trials succeed.

A smooth trial period would see the first results in the 2H2025 and a potential FDA submission in the later part of 2026 and possible approval by the end of 2027, the broker highlights. 

Clinuvel Pharmaceuticals is also pursuing other rare disease indications and developing a generic ACTH drug, further diversifying its portfolio, Bell Potter adds.

Unchanged Buy rating and $22.25 target price.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 5.00 cents and EPS of 69.90 cents.
Bell Potter forecasts a full year FY25 dividend of 5.00 cents and EPS of 72.40 cents.

Morgans

xx/xx/xxxx

1

xxxxxxx xx xxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

CUV STOCK CHART

FNArena News on CUV

1
Australian Broker Call *Extra* Edition – Jun 27, 2024

Jun 27 2024 - Daily Market Reports
2
Rudi’s View: Copper, Lithium, Retailers & TechnologyOne

Jun 27 2024 - Rudi's View
3
Rudi’s View: Quality Reigns, And How To Identify It

May 01 2024 - Rudi's View
4
The Short Report – 21 Mar 2024

Mar 21 2024 - Weekly Reports
5
Weekly Ratings, Targets, Forecast Changes – 15-03-24

Mar 18 2024 - Weekly Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Radiopharm Theranostics

11:00 AM - Small Caps
2
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
3
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps
4
Is The Long Wait For CSL About To End?

May 30 2024 - Technicals
5
Dr Boreham’s Crucible: Invion

May 13 2024 - Small Caps
6
Dr Boreham’s Crucible: Race Oncology

Apr 09 2024 - Small Caps
7
The Power Of New Weight-Loss Drugs

Apr 03 2024 - International
8
Dr Boreham’s Crucible: Neuren Pharmaceuticals

Mar 11 2024 - Small Caps
9
Spotlight On ASX-Listed Cannabis Companies

Jan 31 2024 - Small Caps
10
Transformational Trial Results For Neuren Pharmaceuticals

Dec 20 2023 - Small Caps